Clinical Trial Search

Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score

Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities

Primary: Active Range of Motion of Wrist Extension in the Paretic Side — 37.8; 38; 37.2; 38 degrees

Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants

Primary: Sleep Apnea Diagnosis Rate — 58; 5 participants

Primary: Change in Behavioral Intent to Call 911 — 2.1; 0.4 units on a scale

Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants

Primary: Numbers of Patients With First Occurence of Stroke — 82; 119 participants — p=0.0357

Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale

Primary: Cortical Excitability MEP Amplitude (µV) — 325 µV

Primary: Change in Accuracy of Naming Untrained Pictures (Philadelphia Naming Test:PNT) Pre-treatment to Post-treatment — 5.76; 1.88 score on a scale — p=0.24

Primary: The Percentage of Change in Optical Cerebral Blood Flow (oCBF) During Bolus Normal Saline Compared to Baseline, as Measured by Diffuse Correlation Spectroscopy (DCS)…

Primary: Proportion of Subjects Whose Fugl-Meyer Motor Total Score (FMMS) Improved by ≥ 10 Points at Month 6 From Baseline — 7; 9; 7; 46 Participants — p=0.6743

Primary: Wolf Motor Function Test (WMFT) — 45.17; 49.75; 59.83; 49.80 units on a scale

Primary: Evidence of Carotid Artery or Intracranial Artery Atherosclerosis Confirmed by Vascular Ultrasonography — 96; 1063; 826; 241 artery numbers

Primary: National Institutes of Health Stroke Scale Score — 8.78; 7.80; 8.85; 5.48 units on a scale

Primary: Arm Motor Abilities Test Functional Domain (AMAT - F) — .54 units on a scale

Primary: Utilization of Thrombolysis Among Ischemic Stroke and Transient Ischemic Attack (TIA) Patients — 4; 14 Percent of stroke and TIA patients

Primary: Changes in Brain Activation — 48.5; -30 voxels

Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants

Primary: Percentage of Regions With Collateral Versus Antegrade Blood Flow (Sensitivity) Correctly Identified Using MRI With Xenon Contrast Agent (Specificity) — 81.7; 88.9…

Primary: Wolf Motor Function Test (Time) — 10.21; 29.69; 19.09; 26.05 units on a scale — p=<0.05

Primary: Myelin Basic Protein (MBP) Comparison Between the Two Groups Before and After Treatment — 0.42; 0.64; 0.41; 0.71 pg/ml

Primary: Shift in Modified Rankin Scale (mRS) — 1; 1 score on a scale — p=0.71

Primary: Maximum Expiratory Pressure — 104.31 cm H2O (pressure measurement) — p=.001

Primary: To Assess Changes in Penetration and Aspiration — -0.4; -0.8; -0.8 score on a scale

Primary: Number of Participants With Reperfusion Injury Hemorrhagic Transformation — 3 participants

Primary: Percent Change in Box and Block Test — 20 percent change of number of blocks — p=.04

Primary: Symptomatic Intracerebral Hemorrhage (ICH) — 1; 1 participants

Primary: Attendance Rate — 8 Participants